(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, ...

At a major cancer conference, Merck rolled out some showstoppers — data on drugs on which its business future may depend.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...